The earnings call for Niagen Bioscience presented a robust performance with significant revenue growth, increased net income, and cash generation. The expansion of Niagen Plus and a strengthened patent portfolio were key positive aspects. However, the company faces regulatory challenges and market misconceptions that require ongoing attention.

Company Guidance

During the first quarter of 2025, Niagen Biosciences achieved a remarkable 38% year-over-year revenue increase, reaching $30.5 million, and reported a net income of $5.1 million. The company generated $7.9 million in cash from operations, ending the quarter with $55.6 million in cash and no debt. E-commerce was a significant growth driver, with net sales of $16.8 million, marking a 31% increase year-over-year. The food grade and pharmaceutical grade Niagen ingredient business grew to $8 million, a substantial 95% increase compared to the previous year. Additionally, gross margin improved to 63.4%, up 270 basis points from the previous year's 60.7%. Looking ahead, the company raised its full-year top-line growth outlook to a range of 20% to 25%, reflecting continued confidence in the expanding NAD market and sustained business momentum.

Strong Revenue Growth

In the first quarter of 2025, Niagen Bioscience achieved $30.5 million in revenue, marking a 38% year-over-year increase, with significant contributions from e-commerce and Niagen ingredient business.

Increased Net Income

The company reported a net income of $5.1 million, a substantial improvement from a net loss of $0.5 million in the first quarter of 2024.

Significant Cash Generation

Niagen Bioscience generated $7.9 million in cash from operations and ended the quarter with $55.6 million in cash and no debt.

Expansion of Niagen Plus

Niagen Plus, an intravenous and injection Niagen product, is now available at almost 600 clinics nationwide, with plans to expand to 1,000 clinics by the end of the year.

Patent Portfolio Expansion

A new composition of matter patent was granted, expanding protection for all salt forms of nicotinamide riboside.

Niagen Bioscience (NAGE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NAGE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.02 / -	0.029	―	―	―
Aug 06, 2025	2025 (Q2)	<0.01 / 0.04	0	―
May 07, 2025	2025 (Q1)	0.02 / 0.06	-0.01	700.00% (+0.07)
Mar 04, 2025	2024 (Q4)	0.02 / 0.09	0	―
Oct 31, 2024	2024 (Q3)	<0.01 / 0.03	0.005	480.00% (+0.02)
Aug 07, 2024	2024 (Q2)	-0.02 / 0.00	-0.03	―
May 08, 2024	2024 (Q1)	-0.02 / -0.01	-0.03	66.67% (+0.02)
Mar 06, 2024	2023 (Q4)	-0.03 / 0.00	-0.02	―
Nov 08, 2023	2023 (Q3)	-0.03 / <0.01	-0.01	150.00% (+0.01)
Aug 09, 2023	2023 (Q2)	-0.04 / -0.03	-0.09	66.67% (+0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NAGE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$9.40	$9.61	+2.23%
May 07, 2025	$8.45	$9.24	+9.35%
Mar 04, 2025	$5.60	$8.55	+52.68%
Oct 31, 2024	$3.49	$5.86	+67.91%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Niagen Bioscience, Inc. (NAGE) report earnings?

Niagen Bioscience, Inc. (NAGE) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Niagen Bioscience, Inc. (NAGE) earnings time?

Niagen Bioscience, Inc. (NAGE) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NAGE EPS forecast?

NAGE EPS forecast for the fiscal quarter 2025 (Q3) is 0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing